Top Markets
Coin of the day
Grace Therapeutics, Inc. Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE
Classement en actions #27036
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Prix de l'action
$2.18
Dernière synchronisation: 2026-08-19
Capitalisation boursière
$35.55M
Changement (1 jour)
2.57%
Changement (1 an)
-33.19%
Pays
US
Échange Grace Therapeutics, Inc. (GRCE)

Catégorie

Ratio P/B pour Grace Therapeutics, Inc. (GRCE)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Grace Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Grace Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH